Short Summary
Dr. Falk Pharma has filed an IPR petition seeking cancellation of all 42 claims of Ellodi's ’407 patent covering orally disintegrating corticosteroid tablets, arguing obviousness over Dohil, Grother, Venkatesh and FDA guidance.
Detailed Summary
In a petition filed on October 24, 2024, Dr. Falk Pharma GmbH challenges U.S. Patent No. 9,486,407 owned by Ellodi Pharmaceuticals LP. The patent claims orally disintegrating solid pharmaceutical compositions containing corticosteroids such as budesonide. The petitioner asserts that the claims are obvious in view of prior art references Dohil (US20070111978), Grother (WO2000044351), Venkatesh (US2005/0232988), and the FDA’s 2008 Guidance for Orally Disintegrating Tablets. The petition also cites the European Patent Office’s revocation of equivalent claims and argues that the Advanced Bionics framework does not preclude institution. The request is for the PTAB to institute the IPR and cancel all claims.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Amazon.com Services LLCvsSmart Speaker LLC
A USPTO notice details institution decisions for several IPRs, leaving the status of Amazon’s challenge to Smart Speaker’s patent unresolved.
LEDUP MANUFACTURING GROUP LTD.vsSeasonal Specialties, LLC
LEDup Manufacturing filed a Notice of Appeal challenging the PTAB’s decision that dependent claims 3 and 8 of the ’794 patent remain patentable. The appeal targets the Board’s claim‑construction and other adverse rulings, and is now before the Federal Circuit.
Google LLCvsTelcom Ventures LLC
Google has filed an IPR petition seeking to invalidate 14 claims of Telcom Ventures' smartphone payment patent, alleging obviousness over four prior art references.
Twitch Interactive, Inc. et al.vsRazdog Holdings LLC
Twitch Interactive successfully secured institution of its § 103 IPR challenge against Razdog Holdings LLC's patent. The Board adopted the Petitioner's interpretation of 'real time,' allowing the case to proceed to trial on all claims.
CentralSquare Technologies, LLCvsCarbyne, Ltd. et al.
CentralSquare (CST) opposes Carbyne’s request for a good‑cause extension to seek Director Review in IPR2025‑01179, asserting the deadline was missed intentionally and no claim‑construction conflict exists. The email urges the Director to deny the contingent request.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.